anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The pandemic landscape and people's experiences with testing, infection, and vaccination have changed dramatically over the past two years. Vaccines have become available, testing access in local communities has waxed and waned, and attitudes toward COVID-19 severity and susceptibility have shifted. Navigating the testing-decision landscape is confusing to the public (test availability for free versus charged or requiring insurance; testing and vaccination locations change; PCR versus antigen testing; home tests versus clinically delivered; symptom-based testing, exposure-driven testing, serial testing, resources to trust or not trust, etc.).

This study, referred to as the embedded study, builds off a broader population-based group randomized controlled trial (RCT) to evaluate the effects of a Facilitated Self-Sampling Intervention and Testing Navigation Intervention on testing behaviors. The embedded study will randomly select and assign priority block groups from the RCT to one of three arms - FSSI (n=16), TNI (n=16), or Control (n= 32). The allocation will be at a 2:1:1 rate across the three regions Houston/Harris County, South Texas, and Northeast Texas respectively. Community Health Workers will systematically sample and recruit 20 individuals from each PBG using a random start procedure. Study participants in the intervention arms will be enrolled, complete a baseline survey, receive a brief educational intervention, and complete a follow-up survey. Participants in the control arm will complete a baseline and follow-up survey.
Participants will undergo 30 minutes of AIH. Immediately following, participants will undergo NMES for up to 30 minutes.
FIELD: pharmaceutical chemistry. SUBSTANCE: invention involves new chemical compound of unknown structure, - aqueous-glycerol complex, (2,3-dihydroxypropyl)-ortho-titranate hydrochloride, empirical formula is  , molecular mass is 40209, density of 25% aqueous solution is from 1.033 to 1.058, viscosity is from 1.40 to 2.80. Titanium content is from 2.15 to 2.80. Chloride-ion content is from 0.7 to 1.0. Complex is prepared by interaction of glycerol with butyl-ortho-titanate at the mole ratio 12: 1, respectively, followed by distillation of butanol under vacuum at temperature up to 105 C for 8 h (not less) followed by air bubbling through the reaction mass at temperature below 30 C, water and hydrochloric acid addition up to pH 2.2-3.0, mass holding at temperature below 95 C for 2 h, not above. Also, gel-containing pharmaceutical composition containing active substance is proposed which contains the compound described above as carrier. Active substance can be represented as any medicinal agent or biologically active substance at the following ratio of components, wt.-% active substance 0.01-10.0, and carrier the rest. Composition can also contain diluter taken from the group of organic or inorganic compounds, such as Vaseline, lanolin, water. Carrier 25 wt. -% not less, and diluter the rest. Preparation and its compositions can be used in medicine for treatment of different diseases and as transcutaneous conductor. EFFECT: improved method of complex preparing. 3 tbl
The present invention is directed to a method for treating bronchial constriction in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to produce bronchial dilation. The present invention is also directed to a method for treating airway disease in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in an amount from about 0.0001 millimoles to about 0.005 millimoles. The present invention is further directed to a method for treating airway disease in mammals. The method comprises contacting the mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to prevent bronchial spasm. The present invention is still further directed to a method for treating airway disease in mammals. The method comprises contacting the mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to prevent bronchial constriction.
BACKGROUND: In endovascular aortic repair (EVAR), preemptive embolization of sac branch vessels is effective in preventing postoperative type II endoleak (T2EL). However, this technique has not been widely adopted especially for lumbar arteries (LAs) because of technical difficulties and time constraints. This study aimed to investigate the efficacy of nonselective sac coil embolization, which is a simpler surgical method, in postoperative sac shrinkage for patients at a high risk of T2EL from LAs.
METHODS: We retrospectively assessed 76 patients who underwent elective EVAR for abdominal aortic aneurysm with 4 or more patent LAs or at least 1 patent LA of ≥2 mm at our hospital between January 2014 and December 2022. The patients who underwent sac coil embolization were included in Group Ⅰ (n = 20), and the others were divided into 2 groups: those with an inferior mesenteric artery that was originally occluded or embolized by coils or stent graft bodies (Group Ⅱ, n = 21), and those without that (Group Ⅲ, n = 35). In Group Ⅰ, 0.035-inch coils were inserted into the sac after complete stent graft deployment. The cumulative incidence of sac shrinkage (≥5 mm) was compared between the groups. Further, univariable and multivariable Cox regression analyses were used to determine the predictors of sac shrinkage.
RESULTS: Sac shrinkage (≥5 mm) was observed more frequently in Group Ⅰ (50%) than in Group Ⅱ (19%) and Group Ⅲ (17%) (P = 0.052 and 0.043, respectively). The cumulative incidence of sac shrinkage was significantly higher in Group Ⅰ than in Group Ⅱ (log-rank P = 0.039) and Group Ⅲ (log-rank P = 0.024). Multivariable Cox regression analyses revealed that sac embolization was a significant predictor of sac shrinkage (hazard ratio, 4.23; 95% confidence interval, 1.66-10.8; P = 0.003).
CONCLUSIONS: Nonselective sac coil embolization in EVAR is potentially effective for sac shrinkage in the early postoperative phase in patients at high risk of T2EL from LAs. This simple procedure may improve prognosis after EVAR.
The safety of icatibant was evaluated in three controlled trials that included 223 patients who received icatibant 30 mg (n=113), placebo (n=75), or comparator (n=38). The mean age at study entry was 38 years (range 18 to 83 years), 64% were female, and 95% were white. The data described below represent adverse reactions observed from the two placebo-controlled trials, consisting of 77 patients who received icatibant at a dose of 30 mg SC, and 75 who received placebo.

The most frequently reported adverse reactions (occurring in greater than 1% of patients and at a higher rate with icatibant versus placebo) are shown in Table 1.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The third trial was active-controlled and was comprised of 35 patients who received icatibant 30 mg and 38 patients who received the comparator. Adverse reactions for icatibant were similar in nature and frequency to those reported in Table 1.

In all three controlled trials, patients were eligible for treatment of subsequent attacks in an open-label extension. Patients were treated with Icatibant Injection 30 mg and could receive up to 3 doses of Icatibant Injection 30 mg administered at least 6 hours apart for each attack. A total of 225 patients were treated with 1,076 doses of 30 mg Icatibant Injection for 987 attacks of acute HAE. Adverse reactions similar in nature and frequency were observed to those seen in the controlled phase of the trials. Other adverse reactions reported included rash, nausea, and headache in patients exposed to Icatibant Injection.

The safety of self-administration was evaluated in a separate, open-label trial in 56 patients with HAE. In this trial, the safety profile of Icatibant Injection in patients who self-administered Icatibant Injection was similar in nature and frequency to that of patients whose therapy was administered by healthcare professionals.
JANTOVEN (Warfarin Sodium Tablets, USP) is an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. The chemical name of warfarin sodium is 3-(α-acetonylbenzyl)-4-hydroxycoumarin sodium salt, which is a racemic mixture of the R\- and S-enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. Its empirical formula is C19H15NaO4, and its structural formula is represented by the following:

Crystalline warfarin sodium occurs as a white, odorless, crystalline powder that is discolored by light. It is very soluble in water, freely soluble in alcohol, and very slightly soluble in chloroform and ether.

JANTOVEN tablets for oral use contain: 1 mg, 2 mg, 2½ mg, 3 mg, 4 mg, 5 mg, 6 mg, 7½ mg or 10 mg of warfarin sodium, USP. They also contain:
Eligible patients are randomly assigned to receive intensity-modulated radiotherapy (IMRT) alone or IMRT plus concurrent chemotherapy. IMRT is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor. Concurrent chemotherapy consisted of cisplatin 100 mg/m² every 3 weeks for 3 cycles. The primary endpoint is overall survival (OS). Secondary end points include failure-free survival(FFS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), toxic effects and quality of life. All efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.
PURPOSE: Lympho-vascular invasion (LVI) and perineural invasion (PNI) have been established as prognostic factors in various types of cancers. The preoperative prediction of LVI and PNI has the potential to guide personalized medicine strategies for patients with esophageal squamous cell cancer (ESCC). This study investigates whether radiomics features derived from preoperative contrast-enhanced CT could predict LVI and PNI in ESCC patients.
METHODS AND MATERIALS: A retrospective cohort of 544 ESCC patients who underwent esophagectomy were included in this study. Preoperative contrast-enhanced CT images, pathological results of PNI and LVI, and clinical characteristics were collected. For each patient, the gross tumor volume (GTV-T) and lymph nodes volume (GTV-N) were delineated and four categories of radiomics features (first-order, shape, textural and wavelet) were extracted from GTV-T and GTV-N. The Mann-Whitney U test was used to select significant features associated with LVI and PNI in turn. Subsequently, radiomics signatures for LVI and PNI were constructed using LASSO regression with ten-fold cross-validation. Significant clinical characteristics were combined with radiomics signature to develop two nomogram models for predicting LVI and PNI, respectively. The area under the curve (AUC) and calibration curve were used to evaluate the predictive performance of the models.
RESULTS: The radiomics signature for LVI prediction consisted of 28 features, while the PNI radiomics signature comprised 14 features. The AUCs of the LVI radiomics signature were 0.77 and 0.74 in the training and validation groups, respectively, while the AUCs of the PNI radiomics signature were 0.69 and 0.68 in the training and validation groups. The nomograms incorporating radiomics signatures and significant clinical characteristics such as age, gender, thrombin time and D-Dimer showed improved predictive performance for both LVI (AUC: 0.82 and 0.80 in the training and validation group) and PNI (AUC: 0.75 and 0.72 in the training and validation groups) compared to the radiomics signature alone.
CONCLUSION: The radiomics features extracted from preoperative contrast-enhanced CT of gross tumor and lymph nodes have demonstrated their potential in predicting LVI and PNI in ESCC patients. Furthermore, the incorporation of clinical characteristics has shown additional value, resulting in improved predictive performance.
PURPOSE:An enema having physical and chemical stability, having the same effect as that of glycerin enema, and low side effect such as a stomachache, etc., containing sodium citrate as a main component. CONSTITUTION:An enema containing sodium citrate, preferably trisodium citrate hydrate as a main component. An amount of it blended is preferably 10- 30wt%. An aqueous solution of sodium citrate is found to have the same effect as that of glycerin, and a few clinical demerits glycerin has. Namely, it has no side effect such as a stomachache, and there is sufficient time to open the bowels. The enema is an extremely useful enema which is inexpensive, easily handeable, and has improved long-term safety.
The present invention provides au ultrasonic diagnosis supporting system and method, ultrasonic imaging apparatus. The controller causes a display to display body marks representing the body parts of a subject to be imaged. Furthermore, the controller causes the display to display subjective symptom marks corresponding to the subjective symptoms of a subject to be examined in a location within a body mark that has been designated by an examiner. The examiner conducts ultrasonic imaging by applying an ultrasonic probe to a subject to be examined while checking the location of the subjective symptom marks. The controller links a tomographic image obtained from the imaging to the subjective symptoms and causes a storage to store the same. In the medical examination, the controller causes the display to display the tomographic image and further causes the display to display the subjective symptom marks representing the subjective symptoms linked to the tomographic image.
The invention provides application of siegesbeckic acid to preparation of medicine for treating malaria. The structural formula of siegesbeckic acid is shown in the description. A medicine composition prepared from siegesbeckic acid and a pharmaceutically acceptable carrier is provided. The weight content of the active ingredient siegesbeckic acid in the medicine composition ranges from 5% to 95%. By means of in-vitro anti-malarial activity measurement, the result shows that siegesbeckic acid has good in-vitro plasmodium resisting activity. Therefore, siegesbeckic acid can be used for preparing the medicine for treating malaria, and high clinical application value is achieved.
The invention discloses a composition for treating an inflammatory bowel disease and belongs to the field of medicines. The composition comprises ganoderma lucidum, poria cocos, threonine, serine, cysteine, vitamins C, E and A and beta-carotene. The ganoderma lucidum and the poria cocos have the effects of enhancing blood supply and oxygen supply for a human body. The threonine, the serine and the cysteine are the constituent parts of mucoprotein. The vitamins C, E and A and the beta-carotene have the effects of inhibiting the oxygen free radical activity, removing oxygen free radicals and protecting human body cells. The composition provides nutrients, oxygen and raw materials for development, update and repair of goblet cells and composition of an intestinal tract surface mucous layer barrier by goblet cell secretory mucoprotein. The composition has the obvious effects of eliminating inflammation, repairing intestinal tissues and establishing the normal intestinal tract surface mucous layer barrier of the human body and is an effective formula for treatment of the inflammatory bowel disease.
PURPOSE: Provided are an analgesic composition having sauchinone(SJ-2443) isolated from Saururus choiceness and an analgesic composition thereof. The analgesic composition relieves pain effectively, reduces side effects and improves stability in comparing with the existing analgesic compositions. CONSTITUTION: Dried powder of Saururus choiceness is extracted using mixed solvent of alcohol and water, and the extract is concentrated with vacuum concentration, then is fractionated by solvent fractionation. The fractionated solution is concentrated to produce concentrated extract. The extract from solvent fractionation by diethylether shows an analgesic activity. SJ-2433(formula1) is isolated from the extract by column chromatography. SJ-2433 is used with diluents or supplements, stabilizers, pH controllers, antioxidants in forms of tablet, capsule, oral fluid, syrup, fomentation, ointment, injection.
The present invention provides a nanometer micelle of the vinorelbine preparation for the vein injection, which comprises the vinorelbine of effective amount, the polyethylene glycol-phospholipid and the adjuvant accepted in pharmacy. The nanometer micelle of the vinorelbine preparation for the vein injection is prepared by packaging the vinorelbine into the nanometer micelle. The nanometer micelles with uniform diameter are formed by the vinorelbine and the polyethylene glycol-phospholipid. In the micelle, the hydrophobic core of the vinorelbine is packaged by the carbowax molecule; therefore an inhibitory coating with hydrophilicity is formed. The contaction between the vinorelbine and the enzyme protein molecule in the blood is avoided. The vinorelbine is protected from identification and swallowing by the endothelial system. The circulating time of the medicine in the body is prolonged. In addition, the micelle improves the storing actability and the anti-tumor effect of the vinorelbine. The toxicity of the vinorelbine is reduced.
Emergency treatment of paraesophageal hernias can be carried out through laparotomy or minimally invasive approaches, however, evidence in this regard is weak. The aim of our study was to assess safety and feasibility of the robotic-assisted treatment of paraesophageal hernias in the emergency setting. At the Bellinzona e Valli Regional Hospital, Switzerland, we conducted a retrospective analysis of patients operated on from January 2020 to January 2024 with robotic surgery for emergency presentation of paraesophageal hernias. Demographic and clinical details, operative techniques, and postoperative outcomes were collected and analyzed. Out of 82 patients who underwent robotic-assisted paraesophageal hernia repair, 17 were treated in the emergency setting. Median age was 79 years (IQR 77-85), 3 (17.6%) patients were male, and median BMI was 23.9 kg/m2 (IQR 21.0-26.0). Most frequent presentation symptoms were pain (100%), regurgitation (88.2%), and dyspnea (17.6%). No intraoperative complication, conversion to open surgery or stomach resections were recorded. Two complications of grade 3 according to the Clavien-Dindo classification and one of grade 2 occurred; all were successfully treated until resolution. The median length of hospital stay was 8 days (IQR 5-16). After a mean follow-up of 15.9 months (IQR 6.5-25.6) only two small axial asymptomatic recurrences that required no treatment. Despite limitations, our study demonstrated a very low rate of intra- and postoperative complications, likely supporting the safety and feasibility of robotic-assisted treatment for paraesophageal hernias in emergency settings. Larger studies with a control arm are needed to validate our initial findings.
Individuals will arrive at the Risk Factor Modification Centre, St. Michael's Hospital between the hours of 8:00 and 10:00am after a 10 to 12-hour fast on seven separate mornings. They will not have consumed any antihypertensive medications on the study mornings. Each visit will be separated by a minimum of a week. Since the half-life of ginsenosides in humans is less than 24-hours, to allow for a washout of approximately seven half-lives.

In each of the four studies, when individuals arrive at our clinic on a test day they will first have their weight measured and subsequently rest in the seated position. They will then have a catheter inserted into a forearm vein, which will be kept patent by saline. From this device, a registered intravenous nurse will obtain a series of 7ml blood samples. Blood will be taken at 30-min intervals. Subsequently, individuals will fill out forms detailing their pharmacological regimen for the previous 24-hours and their diet (dinner) and activity (sleep, urination, morning routine) regimen for the previous 12-hours. As well, they will detail any adverse events that they experienced since their previous visit. Individuals will then have their office BP measured with a mercury sphygmomanometer until three consecutive measurements of both SBP and DBP \<5 mmHg different are obtained. At this point, BP should be steady and subjects will be fitted with an ABPM. Measurements will be taken every 5-min for 30-min, for a total of seven measurements. After the seventh measurement (time 0-min), measurements will be taken automatically every 10-min for 180-min. At time 0-min, treatment or placebo capsules will be consumed. At time 60-min a 360-calorie Ensure® breakfast will be consumed within 5-min. Blood samples will be drawn at 30-min intervals, starting at time 0-min. For 24-hours after the ingestion of treatment, a record of any side effects will be detailed by the participants and then provided to us.
"In the study, young adults aged 18-25 will be included, with TMJ dysfunction being measured using the Fonseca Amnestic Index. Based on Fonseca scores, two groups will be formed: those scoring over 20 will be labeled 'with TMJ dysfunction,' while the others will be classified as 'without TMJ dysfunction.' Proprioception will be assessed both through self-reports using the Fremantle Neck Awareness Questionnaire and via joint position sense measured by a CROM device. Body awareness will also be evaluated using the Body Awareness Questionnaire. Pain assessment, including pain threshold, tolerance, and temporal summation, will be conducted using a pressure algometer. The 'pain threshold' will refer to the point at which a person first feels pain, 'pain tolerance' will be the last point that a person can tolerate, and 'temporal summation' will be the pain sensation evaluated after 10 repetitions of the pain threshold.